title: Cost considerations in therapy with myeloid growth factors.
abstract: Costs of biologic response modifiers, specifically myeloid growth factors, are discussed relative to cost offsets they may produce in the total amount spent on health care in patients with certain disease states. Even though the biologic response modifiers granulocyte colony-stimulating factor (filgrastim) and granulocyte-macrophage colony-stimulating factor (sargramostim or molgramostim) are similar in name, they are chemically and biologically different. These differences result in different clinical applications. Administered after myelosuppressive antineoplastic therapy, filgrastim decreases the risk of infection. The growth factors may also be useful in patients undergoing bone marrow transplantation, in nonneutropenic patients with bacterial infections, and in patients with other disease states. Although the myeloid growth factors are somewhat expensive in terms of acquisition cost, their use is usually associated with a decrease in the risk of medical complications requiring health care expenditures, often for hospitalizations or antimicrobials. The precise cost of acquiring and administering myeloid growth factors depends on three interdependent variables: the factor used, the dosage of the drug, and the duration of therapy. Cost offsets may be more difficult to define, but they would include direct cost offsets, such as reduced episodes of febrile neutropenia and fewer, less-intense days of hospitalization or treatment. Sargramostim and molgramostim have demonstrated efficacy when given after bone marrow transplantation; filgrastim has been shown to lower infection rates by at least 50% after myelosuppressive antineoplastic therapy and in patients with severe chronic neutropenia.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Bowyer Oncology Center, School of Medicine, University of California, Los Angeles 90024-6956.
authors.forename: J A
authors.initials: JA
authors.lastname: Glaspy
authors.forename: J
authors.initials: J
authors.lastname: Jakway
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000628:therapy; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003115:Colony-Stimulating Factors / Q000191:economics / Q000627:therapeutic use*; D003365:Costs and Cost Analysis; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000191:economics / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000191:economics / Q000628:therapy; D009503:Neutropenia / Q000191:economics / Q000628:therapy; D011994:Recombinant Proteins / Q000191:economics / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D003115:Colony-Stimulating Factors; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C081222:sargramostim; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000069585:Filgrastim